Immutep Ltd (IMM)

0.573
+0.018(+3.15%)
  • Volume:
    1,066,172
  • Bid/Ask:
    0.570/0.575
  • Day's Range:
    0.550 - 0.575

IMM Overview

Prev. Close
0.555
Day's Range
0.55-0.575
Revenue
420K
Open
0.56
52 wk Range
0.24-0.725
EPS
-0.05
Volume
1,066,172
Market Cap
472.26M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,746,400
P/E Ratio
-
Beta
1.72
1-Year Change
133.88%
Shares Outstanding
850,922,801
Next Earnings Date
Dec 01, 2021
What is your sentiment on Immutep Ltd?
or
Vote to see community's results!

Immutep Ltd News

Immutep Ltd Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Immutep Ltd Company Profile

Immutep Ltd Company Profile

Employees
19
Market
Australia

Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ‘eftilagimod alpha’ or ‘efti’, which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. It has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.